Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1989-7-10
|
pubmed:abstractText |
One hundred and twenty-nine patients with prostatic carcinoma were treated in our hospital. They were between 49 and 88 (average, 70.3) years old and histological diagnosis was adenocarcinoma in all 129 patients; 42 had well differentiated, 55 moderately differentiated, 31 had poorly differentiated carcinomas, and one undeterminated type. Twenty two patients had stage A carcinoma, 18 stage B, 14 stage C and 75 stage D. As the therapeutic principle no castration was done, radiation therapy was delivered to cases with carcinoma more advanced than stage B in combination with estrogen or alone, and antimetabolites were given to some patients. Cryosurgical procedure to prostate was adjunctively used in patients with dysuria. Since 1986, total prostatectomy was carried out in patients with stage B disease and younger than 60 years old, and total combined resection of the urinary bladder and prostate was performed in patients with more advanced than stage C disease. Etoposide was given to patients with recurrent or metastatic lesions. Twenty-two of the 124 patients who did not receive castration surgery were categorized in stage A, 17 in stage B, 14 in stage C, and 71 in stage D. The 5-year survival rate in each stage group was 100%. 56.2%, 70.0%, and 28.8%, respectively, and the statistical difference between stage A and B, and between stage C and D was respectively significant. The relative 5-year survival rate among the total patient group, 71 patients in stage D, 40 patients in stage D treated with hormone therapy, and 15 patients in stage D treated with radiation therapy was 44.5, 28.7, 18.4 and 36.1%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0018-1994
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
57-63
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2729020-Adenocarcinoma,
pubmed-meshheading:2729020-Adult,
pubmed-meshheading:2729020-Aged,
pubmed-meshheading:2729020-Combined Modality Therapy,
pubmed-meshheading:2729020-Drug Administration Schedule,
pubmed-meshheading:2729020-Estrogens,
pubmed-meshheading:2729020-Etoposide,
pubmed-meshheading:2729020-Humans,
pubmed-meshheading:2729020-Male,
pubmed-meshheading:2729020-Middle Aged,
pubmed-meshheading:2729020-Neoplasm Staging,
pubmed-meshheading:2729020-Orchiectomy,
pubmed-meshheading:2729020-Prostatic Neoplasms
|
pubmed:year |
1989
|
pubmed:articleTitle |
[A multimodal treatment of prostatic carcinoma and the 5-year survival rate].
|
pubmed:affiliation |
Division of Urology, Chiba Cancer Center Hospital.
|
pubmed:publicationType |
Journal Article,
English Abstract
|